Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies.

Adachi Y, Tonouchi K, Nithichanon A, Kuraoka M, Watanabe A, Shinnakasu R, Asanuma H, Ainai A, Ohmi Y, Yamamoto T, Ishii KJ, Hasegawa H, Takeyama H, Lertmemongkolchai G, Kurosaki T, Ato M, Kelsoe G, Takahashi Y.

Nat Commun. 2019 Aug 28;10(1):3883. doi: 10.1038/s41467-019-11821-6.

2.

CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.

Tateishi K, Fujihashi K, Yamamoto N, Hasegawa H, Ainai A, Sato K, Iho S, Yamamoto S, Maeyama JI, Odagiri T, Asanuma H.

Vaccine. 2019 Aug 23;37(36):5382-5389. doi: 10.1016/j.vaccine.2019.07.032. Epub 2019 Jul 22.

PMID:
31345642
3.

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing.

Sun L, Kono N, Toh H, Xue H, Sano K, Suzuki T, Ainai A, Orba Y, Yamagishi J, Hasegawa H, Takahashi Y, Itamura S, Ohnishi K.

J Vis Exp. 2019 Mar 15;(145). doi: 10.3791/58804.

PMID:
30933062
4.

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.

Saito S, Sano K, Suzuki T, Ainai A, Taga Y, Ueno T, Tabata K, Saito K, Wada Y, Ohara Y, Takeyama H, Odagiri T, Kageyama T, Ogawa-Goto K, Multihartina P, Setiawaty V, Pangesti KNA, Hasegawa H.

PLoS Pathog. 2019 Jan 3;15(1):e1007427. doi: 10.1371/journal.ppat.1007427. eCollection 2019 Jan.

5.

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

Sano K, Ainai A, Suzuki T, Hasegawa H.

Expert Rev Vaccines. 2018 Aug;17(8):687-696. doi: 10.1080/14760584.2018.1507743. Epub 2018 Aug 27. Review.

PMID:
30092690
6.

Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment.

Ngo DT, Phan PH, Kawachi S, Nakajima N, Hirata N, Ainai A, Phung TTB, Tran DM, Le HT.

BMC Infect Dis. 2018 Jul 3;18(1):294. doi: 10.1186/s12879-018-3215-5.

7.

Application of HTLV-1 tax transgenic mice for therapeutic intervention.

Hasegawa H, Sano K, Ainai A, Suzuki T.

Adv Biol Regul. 2018 May;68:10-12. doi: 10.1016/j.jbior.2018.02.004. Epub 2018 Feb 13. Review.

PMID:
29588208
8.

IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Terauchi Y, Sano K, Ainai A, Saito S, Taga Y, Ogawa-Goto K, Tamura SI, Odagiri T, Tashiro M, Fujieda M, Suzuki T, Hasegawa H.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361. doi: 10.1080/21645515.2018.1438791. Epub 2018 Apr 9.

9.

Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.

Yamazaki T, Nagashima M, Ninomiya D, Ainai A, Fujimoto A, Ichimonji I, Takagi H, Morita N, Murotani K, Hasegawa H, Chiba J, Akashi-Takamura S.

Front Immunol. 2018 Jan 24;9:47. doi: 10.3389/fimmu.2018.00047. eCollection 2018.

10.

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.

Takaki H, Takashima K, Oshiumi H, Ainai A, Suzuki T, Hasegawa H, Matsumoto M, Seya T.

Med Sci (Basel). 2017 Dec 18;5(4). pii: E35. doi: 10.3390/medsci5040035.

11.

The road to a more effective influenza vaccine: Up to date studies and future prospects.

Sano K, Ainai A, Suzuki T, Hasegawa H.

Vaccine. 2017 Sep 25;35(40):5388-5395. doi: 10.1016/j.vaccine.2017.08.034. Epub 2017 Aug 31. Review.

PMID:
28866292
12.

Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection.

Fujimoto Y, Hasegawa S, Matsushige T, Wakiguchi H, Nakamura T, Hasegawa H, Nakajima N, Ainai A, Oga A, Itoh H, Shirabe K, Toda S, Atsuta R, Morishima T, Ohga S.

Sci Rep. 2017 Aug 22;7(1):9128. doi: 10.1038/s41598-017-08030-w.

13.

Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus.

Suzuki T, Ainai A, Hasegawa H.

Vaccine. 2017 Sep 18;35(39):5297-5302. doi: 10.1016/j.vaccine.2017.07.093. Epub 2017 Aug 7. Review.

PMID:
28780981
14.

Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.

Ainai A, Suzuki T, Tamura SI, Hasegawa H.

Viral Immunol. 2017 Jul/Aug;30(6):451-462. doi: 10.1089/vim.2017.0022. Epub 2017 Jun 26. Review.

PMID:
28650274
15.

Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production.

Takaki H, Kure S, Oshiumi H, Sakoda Y, Suzuki T, Ainai A, Hasegawa H, Matsumoto M, Seya T.

Mucosal Immunol. 2018 Jan;11(1):82-96. doi: 10.1038/mi.2017.48. Epub 2017 Jun 15.

PMID:
28612840
16.

Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection.

Kawaguchi A, Suzuki T, Ohara Y, Takahashi K, Sato Y, Ainai A, Nagata N, Tashiro M, Hasegawa H.

PLoS One. 2017 Feb 28;12(2):e0173008. doi: 10.1371/journal.pone.0173008. eCollection 2017.

17.

Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?

Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H.

Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Review.

18.

The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.

Saito S, Ainai A, Suzuki T, Harada N, Ami Y, Yuki Y, Takeyama H, Kiyono H, Tsukada H, Hasegawa H.

Vaccine. 2016 Feb 24;34(9):1201-7. doi: 10.1016/j.vaccine.2016.01.020. Epub 2016 Jan 20.

PMID:
26802605
19.

Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.

Ikeda K, Ainai A, Hasegawa H.

Vaccine. 2015 Nov 9;33(45):6066-9. doi: 10.1016/j.vaccine.2015.09.072. Epub 2015 Oct 1.

PMID:
26432916
20.

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan.

Ainai A, Hasegawa H, Obuchi M, Odagiri T, Ujike M, Shirakura M, Nobusawa E, Tashiro M, Asanuma H.

PLoS One. 2015 Jun 16;10(6):e0130208. doi: 10.1371/journal.pone.0130208. eCollection 2015.

21.

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P, Setiawaty V, Pangesti KN, Odagiri T, Tashiro M, Hasegawa H.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14. doi: 10.1073/pnas.1503885112. Epub 2015 Jun 8.

22.

Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection.

Hasegawa S, Wakiguchi H, Okada S, Gui Kang Y, Fujii N, Hasegawa M, Hasegawa H, Ainai A, Atsuta R, Shirabe K, Toda S, Wakabayashi-Takahara M, Morishima T, Ichiyama T.

Cytokine. 2014 Oct;69(2):206-10. doi: 10.1016/j.cyto.2014.06.006. Epub 2014 Jul 6.

PMID:
24998935
23.

Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.

van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H.

Adv Drug Deliv Rev. 2014 Jul;74:28-34. doi: 10.1016/j.addr.2014.05.011. Epub 2014 May 23. Review.

PMID:
24862579
24.

Plasma Antimicrobial Peptide LL-37 Level Is Inversely Associated with HDL Cholesterol Level in Patients with Type 2 Diabetes Mellitus.

Meguro S, Tomita M, Katsuki T, Kato K, Oh H, Ainai A, Ito R, Kawai T, Itoh H, Hasegawa H.

Int J Endocrinol. 2014;2014:703696. doi: 10.1155/2014/703696. Epub 2014 Mar 26.

25.

The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses.

Sakai K, Ami Y, Tahara M, Kubota T, Anraku M, Abe M, Nakajima N, Sekizuka T, Shirato K, Suzaki Y, Ainai A, Nakatsu Y, Kanou K, Nakamura K, Suzuki T, Komase K, Nobusawa E, Maenaka K, Kuroda M, Hasegawa H, Kawaoka Y, Tashiro M, Takeda M.

J Virol. 2014 May;88(10):5608-16. doi: 10.1128/JVI.03677-13. Epub 2014 Mar 5.

26.

Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.

Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, Tashiro M, Kurata T, Hasegawa H.

Hum Vaccin Immunother. 2013 Sep;9(9):1962-70. doi: 10.4161/hv.25458. Epub 2013 Jun 27.

27.

Analysis of bronchoalveolar lavage fluid in a mouse model of bronchial asthma and H1N1 2009 infection.

Okada S, Hasegawa S, Hasegawa H, Ainai A, Atsuta R, Ikemoto K, Sasaki K, Toda S, Shirabe K, Takahara M, Harada S, Morishima T, Ichiyama T.

Cytokine. 2013 Aug;63(2):194-200. doi: 10.1016/j.cyto.2013.04.035. Epub 2013 May 23.

PMID:
23706975
28.

Spi-B is critical for plasmacytoid dendritic cell function and development.

Sasaki I, Hoshino K, Sugiyama T, Yamazaki C, Yano T, Iizuka A, Hemmi H, Tanaka T, Saito M, Sugiyama M, Fukuda Y, Ohta T, Sato K, Ainai A, Suzuki T, Hasegawa H, Toyama-Sorimachi N, Kohara H, Nagasawa T, Kaisho T.

Blood. 2012 Dec 6;120(24):4733-43. doi: 10.1182/blood-2012-06-436527. Epub 2012 Oct 11.

29.

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.

van Riet E, Ainai A, Suzuki T, Hasegawa H.

Vaccine. 2012 Aug 31;30(40):5893-900. doi: 10.1016/j.vaccine.2012.04.109. Epub 2012 Jul 24. Review.

PMID:
22835738
30.

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.

Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, Gomi Y, Manabe S, Ishikawa T, Okuno Y, Odagiri T, Tashiro M, Sata T, Kurata T, Hasegawa H.

J Med Virol. 2012 Feb;84(2):336-44. doi: 10.1002/jmv.22273.

PMID:
22170556
31.

Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response.

Nakao R, Hasegawa H, Ochiai K, Takashiba S, Ainai A, Ohnishi M, Watanabe H, Senpuku H.

PLoS One. 2011;6(10):e26163. doi: 10.1371/journal.pone.0026163. Epub 2011 Oct 14.

32.

A novel function of the N-terminal domain of PA in assembly of influenza A virus RNA polymerase.

Suzuki T, Ainai A, Nagata N, Sata T, Sawa H, Hasegawa H.

Biochem Biophys Res Commun. 2011 Nov 4;414(4):719-26. doi: 10.1016/j.bbrc.2011.09.142. Epub 2011 Oct 6.

PMID:
22001919
33.

Plasma 25-hydroxyvitamin d is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus.

Meguro S, Tomita M, Katsuki T, Kato K, Oh H, Ainai A, Ito R, Takeda S, Kawai T, Atsumi Y, Itoh H, Hasegawa H.

Int J Endocrinol. 2011;2011:362981. doi: 10.1155/2011/362981. Epub 2011 Jun 6.

34.

Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant.

Ainai A, Tashiro M, Hasegawa H.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:174-82. Epub 2011 Jan 1. Review.

PMID:
21321485
35.

Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids.

Yamazaki T, Nagashima M, Ninomiya D, Arai Y, Teshima Y, Fujimoto A, Ainai A, Hasegawa H, Chiba J.

Jpn J Infect Dis. 2011;64(1):40-9.

36.

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.

Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M, Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H.

J Med Virol. 2010 Oct;82(10):1754-61. doi: 10.1002/jmv.21824.

PMID:
20827774
37.

Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer.

Kuroda M, Katano H, Nakajima N, Tobiume M, Ainai A, Sekizuka T, Hasegawa H, Tashiro M, Sasaki Y, Arakawa Y, Hata S, Watanabe M, Sata T.

PLoS One. 2010 Apr 23;5(4):e10256. doi: 10.1371/journal.pone.0010256.

38.

The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination.

Nakajima N, Hata S, Sato Y, Tobiume M, Katano H, Kaneko K, Nagata N, Kataoka M, Ainai A, Hasegawa H, Tashiro M, Kuroda M, Odai T, Urasawa N, Ogino T, Hanaoka H, Watanabe M, Sata T.

Jpn J Infect Dis. 2010 Jan;63(1):67-71.

39.

Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.

Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H.

J Med Virol. 2010 Mar;82(3):476-84. doi: 10.1002/jmv.21694.

PMID:
20087927
40.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232
41.

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.

Vaccine. 2009 Oct 23;27(45):6276-9. doi: 10.1016/j.vaccine.2009.04.074.

PMID:
19840660
42.

Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.

Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, Tsuji T, Ainai A, Sata T, Okamoto T, Hall WW, Sawa H, Hasegawa H.

Blood. 2009 Oct 1;114(14):2961-8. doi: 10.1182/blood-2008-11-189308. Epub 2009 Aug 5.

43.

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T.

Ther Clin Risk Manag. 2009 Feb;5(1):125-32. Epub 2009 Mar 26.

44.

Renewal of EBV-hybridoma method: efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells.

Ainai A, Kawase T, Ida A, Maeda Y, Ohba H, Ikeda Y, Sato H, Takahashi M, Chiba J.

Hum Antibodies. 2006;15(4):139-54.

PMID:
17522436

Supplemental Content

Support Center